HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:

Environmental Group Opposes FDA Addition Of Triclosan To OTC Monographs

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

An environmental group's efforts to block all non-medical uses of triclosan - including in OTC products - may be futile due to provisions in the National Environmental Policy Act of 1969

You may also be interested in...



Triclosan Use In Cosmetics Gets Tentative OK From CIR Panel

Antimicrobial ingredient triclosan is "safe as used," according to a tentative final ruling issued by the Cosmetic Ingredient Review Expert Panel at its Aug. 31 meeting in Washington

Triclosan Use In Cosmetics Gets Tentative OK From CIR Panel

Antimicrobial ingredient triclosan is "safe as used," according to a tentative final ruling issued by the Cosmetic Ingredient Review Expert Panel at its Aug. 31 meeting in Washington

CIR Panel's Priorities For 2010 Include Triclosan, Amino Acids, Talc

The Cosmetic Ingredient Review's Expert Panel plans to evaluate 300 ingredients in 2010 - including triclosan, one of 17 priorities for the year (see chart: "1Cosmetic Ingredient Review 2010 Priority List")
Table

View full table

Related Content

HBW Insight HBW Insight HBW Insight HBW Insight HBW Insight
Tags:
UsernamePublicRestriction

Register

RS016772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By